InnoCan Pharma Corporation (CSE: INNO)
Canada flag Canada · Delayed Price · Currency is CAD
0.235
+0.025 (11.90%)
Nov 21, 2024, 11:31 AM EST

InnoCan Pharma Company Description

InnoCan Pharma Corporation, a pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally.

The company operates in two segments, Pharmaceuticals and Consumer Wellness. It engages in the research and development of CBD loaded exosomes, as well as operates LPT CBD-loaded liposome platform that facilitates exact dosing and the prolonged and controlled release of CBD into the blood stream for epilepsy and pain management.

The company is also involved in the development and sale of CBD-integrated pharmaceuticals and topical products.

In addition, it develops and markets a portfolio of self-care products for healthier lifestyle. The company offers its products under the Innocan Pharma, R&G Relief & Go, Shir, Synony, and Add On trade names.

InnoCan Pharma Corporation was incorporated in 2018 and is headquartered in Calgary, Canada.

InnoCan Pharma Corporation
Country Canada
Founded 2018
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
CEO Iris Bincovich

Contact Details

Address:
1015, 926 – 5 Avenue SW
Calgary, T2P 0N7
Canada
Phone 403-777-1519
Website innocanpharma.com

Stock Details

Ticker Symbol INNO
Exchange Canadian Securities Exchange
Fiscal Year January - December
Reporting Currency USD
ISIN Number CA45783P1027
SIC Code 2833

Key Executives

Name Position
Roni Kamhi Chief Operating Officer and Chief Executive Officer of BI Sky Global and Director
Iris Bincovich Chief Executive Officer and Director
Ron Mayron Executive Chairman
Nelson Harvey Halpern F.C.A., FCPA Chief Financial Officer
Eyal Flom L.L.M., M.B.A. Director and Company Secretary
Yoram Drucker Founder and Executive Vice President of Business Development